Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

< BACK TO ARCHIVE


2020 Jul 16


J Neurol


http://www.ncbi.nlm.nih.gov/pubmed/32676765?dopt=Abstract

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

Authors

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.
Delmont E, Brodovitch A, Kouton L, Allou T, Beltran S, Brisset M, Camdessanché J P, Cauquil C, Cirion J, Dubard T, Echaniz-Laguna A, Grapperon A-M, Jauffret J, Juntas-Morales R, Kremer L D, Kuntzer T, Labeyrie C, Lanfranco L, Maisonobe T, Mavroudakis N, et al.
J Neurol. 2020 Jul 16.
PMID: 32676765.

Abstract

IgG4 antibodies against neurofascin (Nfasc155 and Nfasc140/186), contactin (CNTN1) and contactin-associated protein (Caspr1) are described in specific subtypes of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Our objective was to assess, in a real-life practice, the incidence, the clinical features and the response to treatment of these forms of CIDP.
Read This Paper